Top Abstract Purchase Related
Home
>
Node
>
Subnode

Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes

Luber, A.D.

Aids Reader 15(12): 692

2005

ISSN/ISBN: 1053-0894
PMID: 16355599
Document Number: 587207
A number of protease inhibitors (PIs) are dependent on an acidic gastric pH for optimal drug dissolution and absorption. As a result, the potential for negative drug interactions with acid-reducing agents exists and could lead to subtnerapeutic drug concentrations, viral breakthrough, and development of drug resistance. Pharmacokinetic evaluations of a number of PIs given with acid-reducing agents have been performed and show varying degrees of effect. Given the possibility of decreases in PI exposures, clinicians should be aware of the potential for a negative interaction when selecting PI-based HAART for patients taking acid-reducing agents.

Document emailed within 1 workday
Secure & encrypted payments

Sherman, K.E.; Shire, N.J.; Cernohous, P.; Rouster, S.D.; Omachi, J.H.; Brun, S.; Da Silva, B. 2005: Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients : Lopinavir-ritonavir versus nelfinavir Clinical Infectious Diseases 41(8): 1186-1195
Gianotti, N.; Poli, A.; Galli, M.; Pan, A.; Rizzardini, G.; Soria, A.; Viale, P.; Di Biagio, A.; Quirino, T.; Viganò, P.; Bonfanti, P.; d'Arminio Monforte, A.; Fortino, I.; Lazzarin, A. 2014: Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study New Microbiologica 37(4): 439-448
Gaillard, M.C.; Reichberg, S.B.; Nogueira, C.M.; Kilroe-Smith, T.A. 1993: Differences in elastase-binding activity of alpha 1-protease inhibitor and alpha 2-macroglobulin for asthma patients and control subjects with various alpha 1-protease inhibitor phenotypes Clinical Chemistry 39(4): 675-679
Czernicki, Z. 1977: Effect of agents increasing the resistance of the vascular wall as well as of trasylol (a protease inhibitor) on experimental brain edema Neurologia i Neurochirurgia Polska 11(4): 457-460
Della Porta, P.; Soeltl, R.; Krell, H.W.; Collins, K.; O'Donoghue, M.; Schmitt, M.; Krüger, A. 1999: Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo Anticancer Research 19(5b): 3809-3816
Ogloblina, O.G.; Belova, L.A.; Malakhov, V.N. 1987: Effective method of isolating an acid-stable protease inhibitor from human urine Voprosy Meditsinskoi Khimii 33(4): 119-124
George, C.; Yesoda, A.; Jayakumar, B.; Lal, L. 2009: A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India Journal of Clinical Pharmacy and Therapeutics 34(1): 33-40
Jackson, M.H.; Payne, H.A. 1995: Bittering agents: their potential application in reducing ingestions of engine coolants and windshield wash Veterinary and Human Toxicology 37(4): 323-326
Djarma, O.ïm.; Nguyen, Y.; Renois, F.; Djimassal, A.; Banisadr, F.; Andreoletti, L. 2014: Continuous free access to HAART could be one of the potential factors impacting on loss to follow-up in HAART-eligible patients living in a resource-limited setting: N'djamena, Chad Transactions of the Royal Society of Tropical Medicine and Hygiene 108(11): 735-738
Buch, H.J. 1970: Treatment of arthrosis with protease-inhibitor Contrykal Das Deutsche Gesundheitswesen 25(20): 947-950
Taylor, B.S.; Hunt, G.; Abrams, E.J.; Coovadia, A.; Meyers, T.; Sherman, G.; Strehlau, R.; Morris, L.; Kuhn, L. 2011: Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa AIDS research and human retroviruses 27(9): 945-956
Nigro, L.; Romano, F.; Tosto, S.; Zagami, A.; Bruno, S.; Nunnari, A. 1999: Severe hepatitis in a HIV-positive subject under treatment with protease inhibitor Italian Journal of Gastroenterology and Hepatology 31(1): 85-86
Chung, M.H.; Drake, A.L.; Richardson, B.A.; Reddy, A.; Thiga, J.; Sakr, S.R.; Kiarie, J.N.; Yowakim, P.; John-Stewart, G.C. 2009: Impact of prior HAART use on clinical outcomes in a large Kenyan HIV treatment program Current HIV Research 7(4): 441-446
Lai, K.H.; Ng, W.W.; Tsai, Y.T.; Tam, T.N.; Lo, G.H.; Chang, F.Y.; Lin, H.J.; Lee, S.D. 1988: Therapeutic effects of low-doses acid-reducing agents in patients with duodenal ulcer Journal of the Formosan Medical Association 87(5): 544-548
Traber, D.L.; Adams, T.; Sziebert, L.; Williams, P.; Traber, L.D. 1984: Failure of a protease inhibitor to affect the cardiopulmonary response to endotoxin when combined with a cyclooxygenase inhibitor Circulatory Shock 13(4): 319-323
2000: Holding option open for subsequent treatment. Beginning therapy with a protease inhibitor MMW Fortschritte der Medizin 142(3 Suppl): 8-9
Ritt, M.J.; Hillebrand-Haverkort, M.E.; ten Veen, J.H. 2001: Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy Acta Chirurgiae Plasticae 43(2): 54-56
Hammer, S.M.; Vaida, F.; Bennett, K.K.; Holohan, M.K.; Sheiner, L.; Eron, J.J.; Wheat, L.Joseph.; Mitsuyasu, R.T.; Gulick, R.M.; Valentine, F.T.; Aberg, J.A.; Rogers, M.D.; Karol, C.N.; Saah, A.J.; Lewis, R.H.; Bessen, L.J.; Brosgart, C.; DeGruttola, V.; Mellors, J.W. 2002: Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial JAMA 288(2): 169-180
Novelli, G.P.; Innocenti, P.; Livi, P. 1993: Gabexate mesilate (FOY), a new synthetic protease inhibitor, in the treatment of shock. An Italian multicenter study Minerva Anestesiologica 59(5): 247-253
Chandrasekhar, A.; Gupta, A. 2011: Nutrition and disease progression pre-highly active antiretroviral therapy (HAART) and post-HAART: can good nutrition delay time to HAART and affect response to HAART? American Journal of Clinical Nutrition 94(6): 1703s-1715s